Andreas Greinacher Selected Research

ChAdOx1 nCoV-19

1/2022	Longitudinal Aspects of VITT.
1/2022	Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient.
1/2022	Heterogeneity of Vaccine-Induced Immune Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination and Safety of Second Vaccination with BNT162b2.
1/2022	Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administration.
1/2022	Laboratory confirmed vaccine-induced immune thrombotic thrombocytopenia: Retrospective analysis of reported cases after vaccination with ChAdOx-1 nCoV-19 in Germany.
1/2022	Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT).
12/2021	Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia.
10/2021	Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein.
6/2021	Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH.
1/2021	Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andreas Greinacher Research Topics

Disease

146	Thrombocytopenia (Thrombopenia) 10/2022 - 04/2001
47	Thrombosis (Thrombus) 10/2022 - 04/2001
35	Hemorrhage 05/2022 - 10/2002
17	Drug-Related Side Effects and Adverse Reactions 01/2022 - 07/2002
13	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 01/2022 - 07/2004
11	COVID-19 10/2022 - 01/2021
9	Transfusion-Related Acute Lung Injury 12/2015 - 01/2010
6	MYH9-Related Disorders 05/2022 - 09/2007
6	Critical Illness (Critically Ill) 01/2021 - 07/2008
6	Sepsis (Septicemia) 01/2018 - 05/2006
5	Infections 02/2022 - 08/2011
5	Neonatal Alloimmune Thrombocytopenia 01/2020 - 05/2006
4	Hemolysis 12/2021 - 08/2007
4	Venous Thrombosis (Deep-Vein Thrombosis) 10/2021 - 04/2003
4	Transfusion Reaction 05/2017 - 01/2010
4	Acute Coronary Syndrome 08/2009 - 05/2004
3	Anaphylaxis (Anaphylactic Shock) 11/2021 - 01/2004
3	Wounds and Injuries (Trauma) 01/2021 - 09/2007
3	Inflammation (Inflammations) 10/2020 - 11/2012
3	Chronic Pancreatitis 01/2020 - 04/2015
3	Bacterial Infections (Bacterial Infection) 01/2019 - 01/2011
3	Venous Thromboembolism 11/2018 - 12/2010
3	Hemophilia A (Haemophilia) 02/2015 - 01/2010
2	Pneumococcal Pneumonia 07/2022 - 12/2020
2	Intracranial Hemorrhages (Intracranial Hemorrhage) 05/2022 - 01/2017
2	Atrial Fibrillation 05/2022 - 06/2016
2	Anemia 02/2022 - 12/2015
2	Neoplasms (Cancer) 08/2021 - 11/2014
2	Autoimmune Diseases (Autoimmune Disease) 10/2020 - 12/2018
2	Thrombotic Thrombocytopenic Purpura 01/2020 - 08/2007
2	Pancreatitis 01/2020 - 04/2015
2	Endocarditis 01/2018 - 08/2007
2	Myocardial Infarction 12/2017 - 11/2016
2	Autoimmune Hemolytic Anemia (Cold Agglutinin Disease) 01/2017 - 09/2015

Drug/Important Bio-Agent (IBA)

121	Heparin (Liquaemin)FDA LinkGeneric 01/2022 - 04/2001
71	AntibodiesIBA 10/2022 - 04/2001
43	Platelet Factor 4IBA 10/2022 - 04/2001
23	VaccinesIBA 10/2022 - 01/2021
19	Immunoglobulin G (IgG)IBA 10/2022 - 03/2005
19	Pharmaceutical PreparationsIBA 01/2020 - 10/2003
17	AnticoagulantsIBA 05/2022 - 08/2003
13	ChAdOx1 nCoV-19IBA 01/2022 - 01/2021
11	Proteins (Proteins, Gene)FDA Link 01/2022 - 06/2005
11	AntigensIBA 01/2021 - 05/2006
11	lepirudin (Refludan)FDA Link 10/2014 - 10/2002
9	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2013 - 10/2005
8	COVID-19 VaccinesIBA 10/2022 - 10/2021
8	argatroban (MPQA)FDA Link 10/2017 - 10/2002
6	Immunoglobulins (Immunoglobulin)IBA 07/2022 - 09/2009
6	Intravenous Immunoglobulins (IVIG)FDA Link 12/2021 - 01/2008
6	EnzymesIBA 10/2021 - 09/2009
6	AutoantibodiesIBA 10/2020 - 04/2007
6	danaparoid (Orgaran)FDA Link 06/2008 - 04/2001
6	bivalirudin (Angiomax)FDA Link 06/2008 - 08/2003
5	Vitamin K FDA Link 05/2022 - 09/2004
5	ChemokinesIBA 01/2018 - 01/2011
5	Immunoglobulin M (IgM)IBA 04/2016 - 05/2006
5	IsoantibodiesIBA 09/2015 - 05/2006
4	Myosin Heavy Chains (Myosin Heavy Chain)IBA 05/2022 - 09/2007
4	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 08/2007
4	Ad26COVS1IBA 01/2022 - 10/2021
4	BNT162 VaccineIBA 01/2022 - 01/2021
4	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 08/2021 - 08/2003
4	polyanionsIBA 10/2016 - 08/2012
4	Glycoproteins (Glycoprotein)IBA 01/2016 - 05/2006
4	HirudinsIBA 05/2008 - 10/2002
3	Hemostatics (Antihemorrhagics)IBA 05/2022 - 01/2010
3	RivaroxabanIBA 01/2022 - 02/2012
3	Blood Group Antigens (Blood Groups)IBA 01/2022 - 04/2015
3	Inosine Triphosphate (ITP)IBA 01/2022 - 04/2013
3	Platelet Membrane GlycoproteinsIBA 01/2022 - 05/2003
3	AntithrombinsIBA 12/2021 - 05/2004
3	ImmunosorbentsIBA 10/2021 - 09/2009
3	human ITGB3 protein (HPA-1a)IBA 01/2020 - 07/2013
3	LigandsIBA 01/2018 - 04/2014
3	Thrombin FDA Link 01/2016 - 10/2008
3	Fondaparinux (Arixtra)FDA Link 07/2015 - 01/2005
3	Isoantigens (Alloantigen)IBA 11/2011 - 01/2011
3	Immunoglobulin A (IgA)IBA 08/2010 - 05/2006
2	Streptococcus pneumoniae plY proteinIBA 07/2022 - 12/2020
2	Tranexamic Acid (AMCA)FDA Link 05/2022 - 05/2015
2	CollagenIBA 01/2022 - 01/2016
2	mRNA VaccinesIBA 01/2022 - 01/2022
2	Blood Coagulation Factors (Coagulation Factor)IBA 12/2021 - 05/2003
2	Hemoglobins (Hemoglobin)IBA 12/2021 - 12/2015
2	Transcription Factors (Transcription Factor)IBA 07/2021 - 05/2021
2	Monoclonal AntibodiesIBA 01/2021 - 07/2013
2	Human Platelet AntigensIBA 10/2019 - 07/2013
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2018 - 05/2009
2	Dacarbazine (DIC)FDA LinkGeneric 01/2018 - 01/2013

Therapy/Procedure

20	Therapeutics 05/2022 - 02/2003
10	Platelet Transfusion (Blood Platelet Transfusions) 02/2020 - 05/2006
6	Critical Care (Surgical Intensive Care) 11/2014 - 04/2001
4	Cardiopulmonary Bypass (Heart-Lung Bypass) 01/2021 - 02/2003
3	Hematopoietic Stem Cell Transplantation 02/2022 - 12/2011
3	Artificial Respiration (Mechanical Ventilation) 12/2020 - 12/2003
3	Renal Replacement Therapy (Therapies, Renal Replacement) 11/2018 - 09/2011
3	Catheters 01/2010 - 04/2001
3	Surgical Amputation (Amputations) 01/2006 - 10/2003
2	Splenectomy 01/2022 - 09/2007